Research Bridge Partners’ Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing

17 Mar, 2021

Research Bridge Partners’ Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing
Photo by Annie Spratt on Unsplash

– Research Bridge Partners announced that one of its portfolio companies, Novosteo, Inc., closed $5.5m in Series A financing to further development of the first-ever targeted bone anabolic agent NOV004.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Novosteo, Inc.’s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly.

Health Care North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: